biOasis Technologies Ord Shs V.BTI

Primary Symbol: V.BTI.H Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > "This is our Watson and Crick moment" Midatech CEO

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Dec 17, 2022 9:03pm

127 Views

Post# 35178101

RE:"This is our Watson and Crick moment" Midatech CEO

"Following expansion of the R&D collaboration agreement with Janssen for encapsulation of its experimental monoclonal antibody, the company is working on developing methods for encapsulation of bispecific T cell engager molecules and antibody-drug conjugates, both of which have shown utility in oncology and present considerable market opportunity." Edison Group November 15, 2022

Don't know if it is possible to make a long-lasting, injectable xB3-Herceptin antibody-drug conjugate.

<< Previous

Bullboard Posts

Next >>

Desert Gold Ventures - A jewel for the investor?